# A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity

> **NCT02567851** · PHASE2 · COMPLETED · sponsor: **University of Birmingham** · enrollment: 38 (actual)

## Conditions studied

- Hodgkin Disease

## Interventions

- **DRUG:** Brentuximab Vedotin

## Key facts

- **NCT ID:** NCT02567851
- **Lead sponsor:** University of Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2016-01-14
- **Final completion:** 2017-10-02
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2018-05-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02567851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02567851, "A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02567851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*